Exploratory work in post-traumatic stress disorder suggests that lower baseline CRHR1 methylation and treatment-related demethylation track greater symptom improvement under CRF1 blockade, hinting that epigenetic or inflammatory stratifiers could identify responder subgroups [123]. The gene discussed is CRHR1; the disease is post-traumatic stress disorder.